Osteoporosıs In Chronıc Kıdney Dısease

Duygu Felek; Mustafa Asım Gedikli

Makale detayları

Osteoporosıs In Chronıc Kıdney Dısease

Yazarlar:

Duygu Felek | Mustafa Asım Gedikli

Yayıncı:

Yozgat Bozok University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Bozok Tıp Dergisi Vol.15 Issue 2, pp.125-131

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001350366

pISSN:

2146-4006

Anahtar kelimeler:

Özet:

 Introduction: Bone mineral density disorders are more common in hemodialysis patients than in the general population. However, treatments to increase bone mineral density may increase vascular complications in hemodialysis patients. Bone mineral supplementation treatment regimens that do not increase hemodialysis-related cardiac mortality are necessary. Method: Thirty-three individuals mean age 72.366.55 years; 20 females, 13 males on hemodialysis for chronic kidney disease were included in the study. Body mass index, calcium, phosphorus, parathormone, bone densitometry results were recorded. In addition, the presence of intravascular calcification in the aorta on radiographs taken within the last 6 months was recorded. The relationships between these parameters were analyzed. Data were analyzed in SPSS. p 0.05 was taken as the significance criterion. Results: When the dexa scores of 33 individuals with stage 5 CKD on hemodialysis were analyzed, the difference between T scores and PTH values was found to be significant p0.020. As PTH increases, the risk of osteoporosis also increases. Osteopenia and osteoporosis were observed less in individuals with high calcium-phosphorus product. However, the difference between intravascular calcification and calcium-phosphorus product was significant p0.004. The calcium-phosphorus product was significantly higher in the group with extensive aortic calcification compared to the other groups. Calcium-containing agents given with osteoporosis treatment increase cardiovascular mortality in stage-5 chronic kidney disease. Conclusion: Bone mineral density disorders should be treated in hemodialysis patients without increasing vascular calcification. In hemodialysis patients with high risk of cardiovascular disease, osteopenic follow-up can be performed by considering the benefit-harm relationship.

 Introduction: Bone mineral density disorders are more common in hemodialysis patients than in the general population. However, treatments to increase bone mineral density may increase vascular complications in hemodialysis patients. Bone mineral supplementation treatment regimens that do not increase hemodialysis-related cardiac mortality are necessary. Method: Thirty-three individuals mean age 72.366.55 years; 20 females, 13 males on hemodialysis for chronic kidney disease were included in the study. Body mass index, calcium, phosphorus, parathormone, bone densitometry results were recorded. In addition, the presence of intravascular calcification in the aorta on radiographs taken within the last 6 months was recorded. The relationships between these parameters were analyzed. Data were analyzed in SPSS. p 0.05 was taken as the significance criterion. Results: When the dexa scores of 33 individuals with stage 5 CKD on hemodialysis were analyzed, the difference between T scores and PTH values was found to be significant p0.020. As PTH increases, the risk of osteoporosis also increases. Osteopenia and osteoporosis were observed less in individuals with high calcium-phosphorus product. However, the difference between intravascular calcification and calcium-phosphorus product was significant p0.004. The calcium-phosphorus product was significantly higher in the group with extensive aortic calcification compared to the other groups. Calcium-containing agents given with osteoporosis treatment increase cardiovascular mortality in stage-5 chronic kidney disease. Conclusion: Bone mineral density disorders should be treated in hemodialysis patients without increasing vascular calcification. In hemodialysis patients with high risk of cardiovascular disease, osteopenic follow-up can be performed by considering the benefit-harm relationship.

 Introduction: Bone mineral density disorders are more common in hemodialysis patients than in the general population. However, treatments to increase bone mineral density may increase vascular complications in hemodialysis patients. Bone mineral supplementation treatment regimens that do not increase hemodialysis-related cardiac mortality are necessary. Method: Thirty-three individuals mean age 72.366.55 years; 20 females, 13 males on hemodialysis for chronic kidney disease were included in the study. Body mass index, calcium, phosphorus, parathormone, bone densitometry results were recorded. In addition, the presence of intravascular calcification in the aorta on radiographs taken within the last 6 months was recorded. The relationships between these parameters were analyzed. Data were analyzed in SPSS. p 0.05 was taken as the significance criterion. Results: When the dexa scores of 33 individuals with stage 5 CKD on hemodialysis were analyzed, the difference between T scores and PTH values was found to be significant p0.020. As PTH increases, the risk of osteoporosis also increases. Osteopenia and osteoporosis were observed less in individuals with high calcium-phosphorus product. However, the difference between intravascular calcification and calcium-phosphorus product was significant p0.004. The calcium-phosphorus product was significantly higher in the group with extensive aortic calcification compared to the other groups. Calcium-containing agents given with osteoporosis treatment increase cardiovascular mortality in stage-5 chronic kidney disease. Conclusion: Bone mineral density disorders should be treated in hemodialysis patients without increasing vascular calcification. In hemodialysis patients with high risk of cardiovascular disease, osteopenic follow-up can be performed by considering the benefit-harm relationship.

 Giriş: Hemodiyaliz hastalarında kemik mineral dansite bozuklukları topluma oranla daha fazla görülmektedir. Ancak kemik mineral yoğunluğunu artırıcı tedaviler hemodiyaliz hastalarında vasküler komplikasyonları artırabilir. Hemodiyalize bağlı kardiyak mortaliteyi artırmayacak kemik mineral desteği tedavi rejimleri gereklidir. Metot: Çalışmaya kronik böbrek hastalığına bağlı hemodiyaliz ile takipli 33 birey ortalama yaş 72.366.55 olup; 20 kadın, 13 erkek dahil edilmiştir. Hastaların beden kitle indeksleri, kalsiyum, fosfor, parathormon, kemik dansitometri sonuçları kaydedildi. Ayrıca bireylerin son 6 ay içerisinde çekilmiş grafilerinde aortada damar içi kalsifikasyon varlığı kaydedildi. Bu parametreler arasındaki ilişkiler incelendi. Veriler SPSS de analiz edildi. p 0.05 önemlilik ölçütüğ alındı. Bulgular: Evre 5 KBH hemodiyalize giren 33 bireyin dexa skorları incelendiğinde T skorları ile PTH değerleri arasındaki farklılık önemli bulundu p0.020. PTH arttıkça osteoporoz riski de artmaktadır. Kalsiyum-fosfor çarpımı yüksek olan bireylerde osteopeni ve osteoporoz daha az gözlendi. Ancak damar içi kalsifikasyon ile kalsiyum-fosfor çarpımı karşılaştırıldığında aralarındaki fark anlamlı bulundu p0.004. Aortada kalsifikasyonun yaygın olduğu grupta kalsiyum-fosfor çarpımının diğer gruplarla karşılaştırıldığında daha anlamlı olarak daha yüksek olduğu gözlendi. Osteoporoz tedavisi ile verilen kalsiyum içerikli ajanlar Evre-5 kronik böbrek hastalığında kardiyovasküler mortaliteyi artırmaktadır. Sonuç: Hemodiyaliz hastalarında vasküler kalsifikasyonu artırmadan kemik mineral dansite bozuklukları tedavi edilmelidir. Kardiyovasküler hastalık riski yüksek olan hemodiyaliz hastalarında fayda zarar ilişkisi gözetilerek osteopenik takip yapılabilir.

Makale detayları

Osteoporosıs In Chronıc Kıdney Dısease

Yazarlar:

Duygu Felek | Mustafa Asım Gedikli

Yayıncı:

Yozgat Bozok University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Bozok Tıp Dergisi Vol.15 Issue 2, pp.125-131

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001350366

pISSN:

2146-4006

Bone Mineral Density Disorder

Osteoporosis

Hemodialysis

Cardiovascular MortalityKemik Minerak Dansite Bozukluğu

Osteoporoz

Hemodiyaliz

Kardiyovasküler Mortalite

Sayı

Makale detayları

Yazarlar: Duygu Felek | Mustafa Asım Gedikli

Yayıncı: Yozgat Bozok University

Ana Başlıklar: İç Hastalıkları

Dergi: Bozok Tıp Dergisi Vol.15 Issue 2, pp.125-131

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001350366

pISSN: 2146-4006

Sayı

Yazarlar:

Duygu Felek | Mustafa Asım Gedikli

Yayıncı:

Yozgat Bozok University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Bozok Tıp Dergisi Vol.15 Issue 2, pp.125-131

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001350366

pISSN:

2146-4006